<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04735354</url>
  </required_header>
  <id_info>
    <org_study_id>CLCZ696BIN01</org_study_id>
    <nct_id>NCT04735354</nct_id>
  </id_info>
  <brief_title>Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction Patients: a Real World Study in India</brief_title>
  <official_title>Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction Patients: a Real World Study in India</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a non-interventional, retrospective EMR analysis of longitudinal prescriptions&#xD;
      in India for a period of 1.5 years. Demographic profile of patients with heart failure with&#xD;
      reduced ejection fraction on sacubitril/valsartan will be recorded.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Index date will be date of 1st prescription of sacubitril/valsartan. Dose titration of&#xD;
      sacubitril/valsartan will be assessed for a period of 6 months post index date.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 27, 2020</start_date>
  <completion_date type="Anticipated">May 2, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Age information</measure>
    <time_frame>Index date</time_frame>
    <description>Age information will be reported</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gender information</measure>
    <time_frame>Index date</time_frame>
    <description>Gender information will be reported</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants by Geographic area</measure>
    <time_frame>idex date</time_frame>
    <description>Geographic area divided into 4 zones- North, South, East and West</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Functional Class (New York Heart Association (NYHA) classification)</measure>
    <time_frame>index date</time_frame>
    <description>The New York Heart Association Functional Classification provides a simple way of classifying the extent of heart failure. It places patients in one of four categories based on how much they are limited during physical activity; the limitations/symptoms are in regard to normal breathing and varying degrees in shortness of breath and/or angina.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Body Mass Index</measure>
    <time_frame>Index date</time_frame>
    <description>Median value body mass index will be reported</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Classification of Heart Failure by etiology</measure>
    <time_frame>1.5 years</time_frame>
    <description>Coronary artery disease, valvular, rheumatic heart disease, others, unknown. It will also be divided into ischemic and non- ischemic etiology</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in ventricular function defined by Left Ventricular Ejection Fraction (LVEF)</measure>
    <time_frame>Index date, 1.5 years</time_frame>
    <description>An ejection fraction (EF) is the volumetric fraction (or portion of the total) of fluid ejected from a chamber with each contraction (or heartbeat).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Medical History</measure>
    <time_frame>1.5 years</time_frame>
    <description>type 2 diabetes, chronic obstructive pulmonary disease (COPD), anemia, chronic renal disease, atrial fibrillation, stroke, hypertension, myocardial infarction</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with notable changes in laboratory parameters</measure>
    <time_frame>Baseline, 1.5 years</time_frame>
    <description>Safety measured by the notable post-baseline changes in laboratory parameters compared to baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Hospitalizations</measure>
    <time_frame>1.5 years</time_frame>
    <description>Hospitalizations due to cardiovascular and non-cardiovascular causes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with concomitant medications</measure>
    <time_frame>up to 6 months pre index date, Up to 6 months post index date</time_frame>
    <description>Concomitant medications classified as-&#xD;
Medications for HF: Diuretics, digitalis, beta-Blockers, ACEi, ARBs, MRA, ivabradine, SGLT2 inhibitors.&#xD;
Medications for non-HF conditions: Anti-diabetic medications other than SGLT2 inhibitors (oral and injectable), statin, antiplatelet therapy, oral anti-coagulants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with other treatments for heart failure</measure>
    <time_frame>1.5 years</time_frame>
    <description>Other treatments for heart failure like implantable cardioverter-defibrillator (ICD), and cardiac resynchronization therapy (CRT).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Persistence to sacubitril/valsartan</measure>
    <time_frame>Up to 12 months post index date</time_frame>
    <description>Defined as time duration from initiation to discontinuation of therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patient discontinuing sacubitril/valsartan</measure>
    <time_frame>month 2, month 4, month 6, month 8 and month 12</time_frame>
    <description>It will be reported as frequency (n) and percentage (%).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum individual dose reached</measure>
    <time_frame>6 months post index date</time_frame>
    <description>Median value of maximum individual dose reached will be reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first dose up-titration</measure>
    <time_frame>6 months post index date</time_frame>
    <description>Median time to first dose up-titration will be reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to target dose</measure>
    <time_frame>6 months post index date</time_frame>
    <description>Median time to target dose will be reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual dose</measure>
    <time_frame>6 months post index date</time_frame>
    <description>The proportion of patients with a starting dose of 50 mg, 100 mg, 200 mg will be reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Titration patterns</measure>
    <time_frame>1.5 years</time_frame>
    <description>Listings will be provided for all titration patterns which evaluated longitudinally at the patient level as follows:&#xD;
Up-titration' corresponds to all patients who experience an initial increase in sacubitril/valsartan dose post-index,&#xD;
'Stable up-titration' corresponds to up-titrated patients who experience no subsequent decrease in sacubitril/valsartan dose&#xD;
'Down-titration' corresponds to all patients who experience an initial dose decrease in sacubitril/valsartan dose post-index, and&#xD;
'Stable down-titration' corresponds to the proportion of down-titrated patients who experience no subsequent up-titration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients being titrated to 100mg from 50mg</measure>
    <time_frame>1.5 years</time_frame>
    <description>Proportion of patients being titrated to 100mg from 50mg will be reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients being titrated to 200mg from 100mg</measure>
    <time_frame>1.5 years</time_frame>
    <description>Proportion of patients being titrated to 200mg from 100mg will be reported</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">600</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>sacubitril/valsartan</arm_group_label>
    <description>Patients administered sacubitril/valsartan by prescription</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sacubitril/valsartan</intervention_name>
    <description>There is no treatment allocation. Patients administered sacubitril/valsartan by prescription that have started before inclusion of the patient into the study will be enrolled.</description>
    <arm_group_label>sacubitril/valsartan</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients ≥18 years with a diagnosis of HFrEF as mentioned in database or heart failure with&#xD;
        a recording of LVEF &lt;40% at index date with a prescription of sacubitril/valsartan will be&#xD;
        included in the study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients ≥18 years with a diagnosis of HFrEF as mentioned in database or heart failure&#xD;
             with a recording of LVEF &lt;40% at or before the index date&#xD;
&#xD;
          -  A prescription of sacubitril/valsartan&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of HF specified as preserved/mid-range ejection fraction&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigational Site</name>
      <address>
        <city>Mumbai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 28, 2021</study_first_submitted>
  <study_first_submitted_qc>January 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 3, 2021</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>heart failure with reduced ejection fraction</keyword>
  <keyword>HFrEF</keyword>
  <keyword>India</keyword>
  <keyword>sacubitril</keyword>
  <keyword>valsartan</keyword>
  <keyword>electronic medical records</keyword>
  <keyword>EMRs</keyword>
  <keyword>retrospective</keyword>
  <keyword>RWE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

